Blackstone and TPG portfolio company Hologic has agreed to acquire Reveal Genomics, a precision oncology company based in Barcelona, Spain, for undisclosed terms.
Reveal Genomics develops genomic diagnostic tests to help personalize cancer treatment. They include HER2DX, which helps optimize therapy for patients with HER2-positive breast cancer. The company uses techniques including computer applications and machine learning to generate new cancer research data.
The acquisition would expand Hologic's oncology diagnostics portfolio. Reveal's tests complement Hologic's existing offering, including the Breast Cancer Index test, a genomic assay that helps inform decisions on extended endocrine therapy for women with HR+ early-stage breast cancer. Together, the new and existing tests are expected to help inform treatment decisions for more women with breast cancer.
Completion of the deal is subject to Spanish regulatory approval and other customary closing conditions.
Source: PE Hub · Summarized by HeadlinesBriefing